BioCentury
ARTICLE | Cover Story

Targeting CDK in triple-negative breast cancer

April 12, 2012 7:00 AM UTC

A team at the University of California, San Francisco has found a dysregulated MYC pathway that underlies the majority of triple-negative breast cancers-a form of the disease with limited treatment options.1 The researchers also showed that inhibitors of cyclin dependent kinase, a target upon which MYC-upregulated cancers are dependent, could selectively kill the triple-negative cancer cells.

The group is planning a clinical trial of an undisclosed cyclin dependent kinase (CDK) inhibitor...